9.22

4.42% 0.39

Pre-market: 9.15 -0.07 -0.76%

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $9.22, with a volume of 1.06M. It is up +4.42% in the last 24 hours and up +0.77% over the past month. 4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Previous Close:

$8.83

Open:

$9.04

24h Volume:

1.06M

Relative Volume:

1.41

Market Cap:

$481.99M

Revenue:

$88.24M

Net Income/Loss:

$-160.90M

P/E Ratio:

-3.4607

EPS:

-2.6642

Net Cash Flow:

$-129.35M

1W Performance:

+6.71%

1M Performance:

+0.77%

6M Performance:

-15.80%

1Y Performance:

+110.02%

1-Day Range:

$8.96

$9.80

1-Week Range:

$8.37

$9.80

52-Week Range:

$3.68

$12.34

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

196

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	9.22	481.99M	88.24M	-160.90M	-129.35M	-2.6642
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Nov-07-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

Jun 12, 2026

4DMT Announces New Employment Inducement Grants - GlobeNewswire

Jun 12, 2026

Jun 10, 2026

Fabry Disease Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutic - Barchart.com

Jun 10, 2026

Jun 05, 2026

Infographic: Study design for ELARA, an open-label, phase 3b trial of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration or diabetic macular edema - Nature

Jun 05, 2026

Jun 03, 2026

FDMT: Gene therapy 4D-150 targets lifelong vision benefit and reduced injections in wet AMD - TradingView

Jun 03, 2026

FDMT: 4D-150 gene therapy shows promise for durable wet AMD treatment with strong safety and scalability - TradingView

Jun 03, 2026

Jun 02, 2026

Insider Sell Alert: David Kirn Sells Shares of 4D Molecular Therapeutics Inc (FDMT) - GuruFocus

Jun 02, 2026

4d molecular therapeutics CEO Kirn sells $19,257 in shares By Investing.com - Investing.com Australia

Jun 02, 2026

4d molecular therapeutics CEO Kirn sells $19,257 in shares - Investing.com

Jun 02, 2026

Insider David Kirn sells 1,922 4D Molecular (NASDAQ: FDMT) shares - Stock Titan

Jun 02, 2026

Monte Rosa (NASDAQ: GLUE) CEO sells 5,466 shares under Rule 10b5-1 plan - Stock Titan

Jun 02, 2026

Jun 01, 2026

[144] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan

Jun 01, 2026

Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares under 10b5-1 plan - Stock Titan

Jun 01, 2026

Number of shareholders of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView

Jun 01, 2026

Opus Genetics Slides Ahead of June Test - Bez Kabli

Jun 01, 2026

May 30, 2026

IonQ Aktie: Two Sigma kauft 2,17 Millionen Aktien - Finanztrends

May 30, 2026

May 27, 2026

4D Molecular Therapeutics (FDMT) Gains 1.6% as Stock Holds Above SupportThematic ETF Flow - The Legal Advocate

May 27, 2026

4DMT to Participate in Upcoming Investor Conferences - The Globe and Mail

May 27, 2026

May 20, 2026

Pittsburgh Post-Gazette - FinancialContent

May 20, 2026

4D Molecular Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus

May 20, 2026